Czech National Bank Raises Stake in CVS Health Corporation $CVS

Key Points

• Czech National Bank increased its CVS Health stake by 4.8% in the second quarter, bringing its holdings to 363,178 shares valued at approximately $37.6 million. Institutional investors and hedge funds collectively own 80.66% of CVS.
• CVS reported strong second-quarter results, with adjusted EPS of $2.58 and revenue of $106.1 billion, beating estimates. The company raised its 2026 adjusted EPS guidance to $7.90–$8.10 and operating cash-flow guidance to at least $11.5 billion.
• Analysts remain broadly positive, with 22 Buy ratings and a consensus “Moderate Buy” rating, but investors are watching potential 2027 Caremark risks, including 340B changes and declining membership. Shares were trading down 2.8% at $96.32, while the company maintained a $0.665 quarterly dividend.

Czech National Bank grew its holdings in CVS Health Corporation (NYSE:CVS - Free Report) by 4.8% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 363,178 shares of the pharmacy operator's stock after buying an additional 16,697 shares during the period. Czech National Bank's holdings in CVS Health were worth $37,571,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in CVS. Swiss RE Ltd. acquired a new position in CVS Health in the 4th quarter valued at about $26,000. Sankala Group LLC acquired a new stake in CVS Health during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd grew its stake in shares of CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator's stock valued at $26,000 after purchasing an additional 281 shares during the last quarter. Mcguire Capital Advisors Inc. purchased a new stake in shares of CVS Health during the fourth quarter worth approximately $28,000. Finally, Ares Financial Consulting LLC acquired a new stake in shares of CVS Health during the fourth quarter worth $29,000. Institutional investors and hedge funds own 80.66% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on CVS shares. Morgan Stanley upped their price objective on shares of CVS Health from $106.00 to $111.00 and gave the stock an "overweight" rating in a research report on Thursday, June 4th. Robert W. Baird set a $107.00 price objective on shares of CVS Health in a research report on Thursday. UBS Group boosted their target price on CVS Health from $122.00 to $126.00 and gave the stock a "buy" rating in a research report on Thursday. HSBC reissued a "hold" rating and set a $103.00 target price on shares of CVS Health in a research note on Monday, July 6th. Finally, Wells Fargo & Company lifted their price target on CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a research note on Monday, July 13th. Twenty-two research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $106.46.

Insider Buying and Selling

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the company's stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company's stock, valued at approximately $450,877,466.55. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 3,372,000 shares of company stock worth $317,473,598 in the last quarter. 0.85% of the stock is currently owned by insiders.

Key Headlines Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS reported adjusted earnings of $2.58 per share, well above the $1.87 analyst consensus, while revenue rose 7.3% year over year to $106.1 billion. All three major segments—Aetna insurance, pharmacy services and health services—contributed to the result. CVS blows past estimates, hikes guidance as insurance unit continues to improve
• Positive Sentiment: The company raised its full-year 2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and increased operating cash-flow guidance to at least $11.5 billion. Improved medical-cost performance at Aetna, stronger drug revenue and a more profitable pharmacy mix supported the outlook. CVS Health reports strong second-quarter results and raises full-year guidance
• Positive Sentiment: CVS also expanded its weight-management strategy through a collaboration with Eli Lilly, offering additional access to Zepbound and other GLP-1 treatments through CVS Pharmacy and its digital care platform. The initiative could support pharmacy traffic and future growth. CVS Health enhances direct-to-consumer weight-management offerings
• Neutral Sentiment: The improving Aetna Medicare Advantage business is a key turnaround catalyst, but management’s commentary suggests the recovery is still being evaluated against changing healthcare costs and reimbursement conditions. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks
• Negative Sentiment: Investors remain concerned about 2027 pressure on Caremark from potential 340B program changes and declining membership. Those risks could offset current insurance improvements and help explain why the stock fell despite the earnings beat and higher 2026 outlook. CVS Q2 earnings call pairs Aetna recovery with 2027 PBM risks

CVS Health Trading Down 2.8%

Shares of CVS opened at $96.32 on Friday. CVS Health Corporation has a twelve month low of $62.55 and a twelve month high of $110.68. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $122.90 billion, a P/E ratio of 25.48, a PEG ratio of 0.90 and a beta of 0.61. The firm's 50-day moving average is $102.17 and its two-hundred day moving average is $87.68.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. The company's revenue for the quarter was up 7.3% on a year-over-year basis. During the same period last year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, research analysts predict that CVS Health Corporation will post 8 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.8%. CVS Health's payout ratio is currently 70.37%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source